Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients

Fig. 2

Percentage of patients achieving pCR in E2F4 activity groups after stratification on clinicopathological characteristics in the Hatzis dataset. a Percentage of patients achieving pCR with low (white), intermediate (grey), and high (dark grey) E2F4 activity groups for all, ER-positive, and ER-negative patients, respectively. b Percentage of patients achieving pCR with low (white), intermediate (grey), and high (dark grey) E2F4 activity groups in patients with different tumor stage. c Percentage of patients achieving pCR with low (white), intermediate (grey), and high (dark grey) E2F4 activity groups in patients belonging to different molecular subtypes. In all panels, horizontal dotted line indicates the percentage of pCR patients without stratifying based on E2F4 activity. P-values were calculated using the χ2 test

Back to article page